SPS

Direct randomised comparisons of NOACs vs VKA in AF patients undergoing PCI are not available, therefore the recommendations are based on post hoc analyses of the RELY (dabigatran) and ARISTOTLE (apixaban) comparison with warfarin in stroke & systemic embolism prevention trials in patients with AF1. ................
................